Retinoid X receptor (RXR) occupies a central position within the nuclear receptor superfamily, serving as an obligatory partner to numerous other nuclear receptors, including vitamin D receptor (VDR). In the current study, we examined whether phosphorylation of RXRa at serine 260 affects VDR/RXR and VDR interacting protein (DRIP) 205 coactivator recruitment, interactions, and binding of the VDR/human RXRa (hRXRa)/DRIP205 complex to chromatin. Serine 260 is a critical amino acid on the hRXRa that is located in close spatial proximity to regions of coactivator and corepressor interactions. Using fluorescence resonance energy transfer and immunofluorescence studies, we showed that the physical interaction between hRXRa and DRIP205 coactivator was impaired in human keratinocytes with the ras oncogene (HPK1Aras) or transfected with the wild-type hRXRa. Furthermore, the nuclear colocalization of VDR/DRIP205, hRXRa/DRIP205, and VDR/hRXRa/DRIP205 complex binding to chromatin is impaired in the HPK1Aras cells when compared with the normal human keratinocytes (HPK1A cells). However, transfection with the nonphosphorylatable hRXRa (S260A) mutant or treatment with the mitogen-activated protein kinase (MAPK) inhibitor UO126 rescued their nuclear localization, interaction, and binding of the complex to chromatin in the HPK1Aras cells. In summary, we have demonstrated, using highly specific intracellular tagging methods in live and fixed cells, important alterations of the vitamin D signaling system in cancer cells in which the ras-raf-MAPK system is activated, suggesting that specific inhibition of this commonly activated pathway could be targeted therapeutically to enhance vitamin D efficacy. 
T he biologically active form of vitamin D 3 , 1a,25-dihydroxyvitamin D 3 [1a,25(OH) 2 D 3 ] , is a pleiotropic nuclear hormone involved in a broad range of physiological effects. Primarily recognized for the regulation of calcium homeostasis (1-3), 1a,25(OH) 2 D 3 is now known to have widespread effects on immune function, as well as cellular growth, differentiation, and apoptosis (4) . It blocks cell proliferation in several cancer models, including melanoma, myeloid leukemia (5) , and carcinomas of the prostate (6) , pancreas (7) , breast (8) (9) (10) (11) , kidney (12) , colon (13) , and head and neck (14) (15) (16) (17) (18) (19) (20) (21) (22) . The genomic effects of 1a,25(OH) 2 D 3 are mediated through the nuclear vitamin D receptor (VDR), which belongs to the nuclear receptor transcription factor superfamily. Active VDR binds preferentially as a heterodimer with the retinoid X receptor (RXR) (23) (24) (25) (26) (27) (28) (29) (30) (31) to hexameric repeats on specific DNA sequences referred to as vitamin D response elements (32) (33) (34) in the promoter regions of 1a,25(OH) 2 D 3 target genes. As with other nuclear receptors, the binding of 1a,25(OH) 2 D 3 to the RXR/VDR heterodimer functions to recruit additional cofactors that play an essential role in transcription (35, 36) . A wide range of nuclear receptor cofactors that perform distinct functions at target promoters has been identified, including chromatin modification and remodeling and recruitment of the RNA polymerase II holoenzyme (37) . VDR can recruit the VDR interacting protein (DRIP) complex, which consists of a group of some 10 to 13 proteins (38) . Among the DRIP complexes is DRIP205 [also known as thyroid receptor associated protein-220 (TRAP220) or MED1 subunit of the mediator complex], which is recognized as the single protein that mediates direct interaction with the VDR (39, 40) . VDR is also known to interact with members of the p160 class of coactivators, including steroid receptor coactivator (SRC)-1, transcriptional mediator/intermediary factor-2 (TIF2)/glucocortoid receptor interacting protein (GRIP) 1, and activator of the thyroid and retinoid receptor (ACTR)/amplified in breast cancer 1 (AIB1)/p300/cAMP response element binding protein (CPB)-binding protein (pCIP), which can act directly to catalyze selective acetylation of histones and indirectly to recruit additional regulatory molecules such as histone acetyltransferases capable of eliciting related changes in chromatin structure (40) . The interaction of the VDR with comodulators such as DRIP205 as well as SRC1 and TIF2/glucocortoid receptor interacting protein 1 is mediated through nuclear receptor interaction domains containing LXXLL motifs that associate directly within the activation function (AF)-2 region of nuclear receptors (41, 42) (Fig. 1) . Recent crystallographic studies have defined the interaction between the LXXLL motif and the AF-2 cleft of the nuclear receptors created upon ligand binding (43, 44) . Structural studies have demonstrated that a hydrophobic channel (AF-2) is exposed on the surface of the ligand-binding domain (LBD) as a consequence of ligand binding (44) (45) (46) . This channel accommodates the LXXLL a-helix, which is held in place by hydrophobic interactions and a charged clamp involving two amino acids (lysine and glutamate) that are conserved throughout the nuclear receptor family (41, 47) . Different cofactors have been shown to have variable numbers of functional LXXLL motifs (48) .
Ras-activating mutations are some of the most frequent somatic mutations in human cancers (49) . Ras activation leads to the stimulation of the mitogenactivated protein kinase (MAPK) pathway and contributes to cancer progression and development (49) (50) (51) (52) (53) (54) . Several groups including ours have reported that MAPK activation modulates the transcriptional activity of 1,25(OH) 2 D 3 (55) (56) (57) (58) . We previously reported that overexpression of H-ras in human keratinocytes activates the MAPK pathway resulting in the inhibition of transactivation of known vitamin D target genes and resistance to the growth inhibitory action of 1,25(OH) 2 D 3 (59) . We also demonstrated that this resistance was due to phosphorylation of the VDR heterodimeric partner human RXR a (hRXRa) on a critical amino acid serine 260 located in close spatial proximity to regions of coactivator and corepressor interactions. Furthermore, we have shown that hRXRa phosphorylation interferes with DRIP205 coactivator recruitment and binding (60) .
In the current study, we used fluorescence imaging techniques to examine further the interactions between the human VDR (hVDR)-hRXRa-DRIP205-DNA complex and to determine the mechanism by which constitutive MAPK activation alters coactivator recruitment and hVDR-hRXRa-DRIP205 complex binding to DNA. We hypothesized that RXRa phosphorylation within the v loop would alter the conformational ensemble of hRXRa and that the dynamics would further lead to defects in coactivator interaction, recruitment, and Vitamin D signaling. Our specific goals were to (1) understand how hRXRa phosphorylation at serine 260 affects DRIP205 nuclear localization, (2) understand whether blocking phosphorylation by the use of a MAPK inhibitor or a nonphosphorylatable hRXRa mutant would restore DRIP205 coactivator interaction and recruitment to VDR-RXRa thereby stabilizing the complex in the ras-transformed keratinocytes, (3) understand how hRXRa phosphorylation affects VDR/hRXRa/DRIP205 complex binding to DNA, and (4) use molecular modeling to determine the effects of RXRa phosphorylation on RXRa/DRIP205 interaction and conformation change.
Experimental Procedures
Reagents 1a,25(OH) 2 D 3 was purchased from Sigma (St. Louis, MO), and stock solutions were prepared in ethanol. The MEK1/2 inhibitor UO126 (1,4-diamino-2,3-dicyano-1,4-bis [2-aminophenylthio] butadiene) was purchased from Promega (Madison, WI), and stock solutions were prepared in dimethyl sulfoxide (DMSO 
Cell lines and culture
The normal human keratinocytes (HPK1A) cell line (RRID: CVCL_D890) was previously established by stably transfecting normal human keratinocytes with human papillomavirus type 16 (59) . In culture, these cells have an indefinite life span but retain differentiation properties characteristic of normal keratinocytes and are nontumorigenic when injected into nude mice. These immortalized cells were then transformed into the malignant human keratinocytes with the ras ocogene (HPK1Aras) cell line (RRID: CVCL_D891) after transfection with a plasmid carrying an activated Ha-ras oncogene (59) . HPK1Aras cells are malignant cells that form colonies in soft agar and also produce invasive tumors when transplanted into nude mice. The cells were grown in Dulbecco's modified Eagle medium (DMEM) (Gibco) supplemented with 2 mM glutamine, 100 IU/mL penicillin, 100 mg/mL streptomycin, and 10% fetal bovine serum (FBS) and passaged twice weekly in 100-mm Falcon plates (Corning, NY).
Subcloning of hVDR plasmids
VDR/pSG5 plasmid was a kind gift from Dr. John White's laboratory (McGill University, Montreal, Canada). The expression vector was originally constructed by inserting a 2.1-kb EcoRI fragment containing the entire coding region of the hVDR into the EcoRI site of pSG5. VDR-cyan fluorescent protein (CFP), VDR-green fluorescent protein (GFP), VDR-yellow fluorescent protein (YFP), and VDR-mCherry plasmids were constructed by polymerase chain reaction (PCR) amplification of hVDR sequence using hVDRpSG5 as a template, and forward GGTTAC CTCGAG ATG GAG GCA ATG GCG GCC AGC ACT TCC CTG and reverse GTTAC CCG CGG AGA GGA GAT CTC ATT GCC AAA CAC TTC G primers were designed with XhoI and SacII restriction sites. The hVDR PCR product was ligated to the GFP variants, a generous gift from Dr. Stephane Laporte (McGill University, Montreal, Canada), and mCherry (Clontech).
Subcloning of hRXRa plasmids
The hRXRa wild-type (WT) plasmid was a kind gift from Dr. Ronald Evans' laboratory (Salk Institute, CA). The hRXRa S260A mutant plasmid was previously constructed in our laboratory (55) (56) (57) 60) . The hRXRaWT and the hRXRa S260A mutant fluorescent GFP variants (i.e., GFP, CFP, YFP, and mCherry) were constructed by PCR amplification of hRXRWT and the hRXRa S260A mutant sequences using hRXRa WT and the hRXRa S260A mutant as templates, and forward GGTTAC CTCGAG ATG GAC ACC AAA CAT TTC CTG C and reverse GTTAC CCG CGG AGA AGT CAT TTG GTG CGG CGC CTC CAG C primers were designed to create new XhoI and SacII restriction sites. The resulting amplified PCR products were ligated to mCherry and the GFP variants, respectively.
Subcloning of DRIP205 plasmids
pcDNA3-DRIP205 expression plasmid was kindly provided by Dr. Michael Degarabedian's laboratory (New York University Medical Center, NY). The DRIP205 fluorescent GFP variants (i.e., GFP, CFP, YFP, and mCherry) were constructed by PCR amplification of DRIP205 as templates using (forward) 5 0 -GA CAT AAC CGG TTT GTA ATT CCC AAT CAG GGC CAC ATC-3 0 and (reverse) 5 0 -GA CAT AAC CGG TTT GTA ATT CCC AAT CAG GGC CAC ATC -3 0 primers. The resulting amplified PCR products were digested with KpnI and AgeI and ligated to mCherry and the GFP variants, respectively.
Subcloning of LXXLL and AXXAA plasmids LXXLL-GFP motif was kindly provided by Dr. Sylvie Mader (University of Montreal, Montreal, Canada). The LXXLL fluorescent GFP variants (i.e., GFP, CFP, YFP, and mCherry) were constructed by PCR amplification of LXXLL as templates using (forward) 5 0 -GA CAT AAC CGG TTT GTA ATT CCC AAT CAG GGC CAC ATC -3 0 and (reverse) 5 0 -GA CAT AAC CGG TTT GTA ATT CCC AAT CAG GGC CAC ATC -3 0 primers. The resulting amplified PCR products were digested with KpnI and AgeI and ligated to mCherry and the GFP variants, respectively. The AXXAA fluorescent GFP variants were made by using similar LXXLL-GFP motif constructs in which leucine residues were replaced by alanine.
Transfection
HPK1A and HPK1Aras cells were maintained in DMEM containing 10% FBS. For experimentation, cells were plated overnight in six-well plates on No. 1 coverslips (Fisher) for fixed cells or 35-mm MatTek glass-bottom dishes (MatTek Corp., Ashland, MA) for live cell experiments. Cells were plated at 8 3 10 4 cells/well (HPK1A) and 6 3 10 4 cells/well (HPK1Aras) in DMEM containing 10% FBS. The next day, the medium was changed to serum-free DMEM for an hour prior to initiating the experiment. Transfection was carried out in serum-free DMEM with FuGENE HD at a FuGENE HD/DNA transfection ratio of 6 mL/2 mg DNA (Roche Applied Science, Indianapolis, IN). The cells were transfected with vectors encoding constructs of hRXRa-GFP, hRXRa-mCherry (2.0 mg) or hVDR-CFP, hVDR-GFP, hVDR-mCherry (2.0 mg), DRIP205-GFP, DRIP205-mCherry, LXXLL-GFP, or AXXAA-YFP (2.0 mg). In cotransfection studies, a total of 2 mg of the cotransfected vectors was used per well. After 4 hours of incubation, the medium was supplemented with 10% FBS (by adding 200 mL of FBS/well). Following a 30-hour incubation, the medium was changed to DMEM containing 5% FBS and incubated overnight. The next day, cells were treated with vehicle (ethanol + DMSO, 0.1% volume-to-volume ratio) or 1,25(OH) 2 D 3 (10 -7 M) and UO126 (10 26 M) alone or a combination of UO126 and 1,25(OH) 2 D 3 for 4 hours. For real-time live-cell microscopy, the transfected cells were first transferred onto a heated stage at 37°C for drug treatments and data acquisition. For fixed-cell experiments, the cells were washed with phosphate-buffered saline (PBS) after the treatment and fixed for 15 minutes in 4% paraformaldehyde at 37°C. Following fixation, cells were rewashed in PBS and mounted using Shandon Immu-Mount mounting medium (Thermo Fisher Scientific, Pittsburgh, PA). For subcellular localization studies, following fixation and rewashing, the cells were stained with either 4 0 ,6-diamidino-2-phenylindole (DAPI) or Hoechst 33342 dye (Invitrogen) for 10 minutes and then mounted using Shandon Immu-Mount mounting medium (Thermo Fisher Scientific). Imaging was carried out the next day using a Zeiss LSM 780 confocal microscope (Carl Zeiss, Inc., Jena, Germany).
Immunofluorescence staining
Cells were grown in six-well plates on 22-mm No. 1 glass slides (Thermo Fisher Scientific). At experimental end points, the coverslips were fixed in 4% formaldehyde at room temperature for 10 minutes. After rinsing with PBS, cells were permeabilized for 10 minutes with 0.25% Triton X-100 in PBS, washed in PBS 3 times for 5 minutes, and blocked with 1% bovine serum albumin in PBS/Tween 20 for 30 minutes. Cells were incubated with anti-VDR (rabbit at 1:50 dilution), anti-RXR (mouse at 1:50 dilution), anti-DRIP205 (rabbit at 1:50 dilution), or a combination of rabbit-anti-VDR and mouse-anti-RXR antibodies, rabbit-anti-DRIP205 and mouse-anti-VDR antibodies, or rabbit-anti-DRIP205 and mouse-anti-RXR antibodies (at 2:100 dilution) overnight at 4°C. Samples were then incubated with the corresponding goat anti-rabbit Alexa Fluor-488 and goat anti-mouse Cy3-conjugated secondary antibodies (1:500; Thermo Fisher Scientific). Following rewashing with PBS, slides were counterstained with either DAPI or Hoechst 33342 dye (Invitrogen) for 10 minutes and then mounted using Shandon Immu-Mount mounting medium (Thermo Fisher Scientific). Samples were visualized the next day using a Zeiss LSM 780 confocal microscope using a 363 numerical aperture (NA) 1.4 oil immersion objective and appropriate filter sets (Carl Zeiss, Inc.).
Fluorescence microscopy, time-lapse imaging, and image processing Receptor expression and subcellular distribution using confocal microscopy GFP, hVDR-GFP, hRXRaWT-GFP, hRXRamut-GFP, and DRIP205-GFP expression vectors were monitored by viewing and counting fluorescing cells using a Plan-Neofluar 340/1.3 oil objective and 488-nm excitation and 515-to 565-nm emission filters (Carl Zeiss, Inc.). To monitor subcellular distribution of the receptors, at least 10 healthy cells were observed at random from at least 10 fields. Repeated experiments were done using the same parameters. Z-stacks of double-labeled images were collected to account for total cellular fluorescence.
Morphometric analysis of subcellular localization
For evaluation of nuclear/cytoplasmic signal distribution, confocal images were taken of each fluorescing cell. A single optical slice was taken of each cell with a focus set to maximize the circumference of the nucleus. At least 10 cells were evaluated for each experimental condition. Cells that showed clear morphological changes due to protein overexpression were excluded from statistical analysis. Image analysis was performed using the ImageJ version 1.41 software (National Institutes of Health, Bethesda, MD; RRID: SCR_003070) to determine the nuclear fluorescence (F n ), cytoplasmic fluorescence (F c ), and background fluorescence (F b ). Briefly, a mean density measurement of pixel numbers was made on a nonsaturated region of interest (ROI) consisting of the total nucleus, the whole cell (nucleus and cytoplasmic compartments combined), and a background region outside of the cell. The ratio of nuclear to cytoplasmic fluorescence (F n/c ) was then determined according to the following formula:
Data are presented as mean 6 standard error (SE) (61, 62 2 D 3 . Treatments were carried out for 4 hours before fixing, mounting, and fluorescence resonance energy transfer (FRET) data acquisition using a Zeiss LSM 780 confocal microscope with a Zeiss 63 3 NA 1.3 Neofluar oil objective and a chamber to maintain a temperature of 37°C and 5% CO 2 (Carl Zeiss, Inc.). To assay dequenching of donor after photobleaching, a series of eight images of the GFP channel was taken. mCherry within the nucleus was bleached after image 4 by scanning with the 561-nm laser line at maximum intensity. GFP intensities inside the nucleus were compared between the immediately prebleached image (image 4) and the postbleached image (image 5). Dequenching was defined as nuclear GFP intensity in image 4 divided by nuclear GFP intensity in image 5. The remainder of the image sequence served as a control for focus stability. At least 10 cells per treatment were photobleached for each experiment. Experiments were repeated at least twice. To calculate FRET percentage, the fluorescence intensities of three ROIs, a region in close proximity to the cell (background), a region in the nucleus that was photobleached (bleached region), and a region of the nucleus that was not bleached (unbleached region), were selected, and data were acquired for both mCherry and GFP. The fluorescent intensities of GFP immediately before the bleach and immediately after the bleach were next background corrected by subtracting fluorescence intensity of the background region in the GFP channel of the same image. The prebleach and postbleach GFP corrected intensities were then used to calculate the percentage dequenching, which is a measure of FRET in this experimental design. At least 10 images were analyzed per experimental condition. Percentage dequenching was calculated as follows: dequenching % = (GFP_corrected postbleach/GFP_corrected prebleach) 3 100. In this measure, 100% represents a baseline with no change in fluorescence, indicative of no substantial FRET, although values greater than 100% are consistent with FRET prior to dequenching (63) (64) (65) . FRET analysis using CFP/YFP probes has previously been published (66) .
Fixed-cell imaging and FRET microscopy in antibody costained cells
HPK1A and HPK1Aras cells were grown on 22-mm No. 1 coverslips, treated, fixed, and permeabilized as discussed previously under confocal immunofluorescence microscopy. Cells were incubated with combination of rabbit-anti-VDR and mouse-anti-TRAP220 (DRIP205) or rabbit anti-RXR and mouse anti-TRAP220 (DRIP205) antibodies (at 2:100 dilution) overnight at 4°C. Samples were then incubated with the corresponding goat anti-rabbit Alexa Fluor-488 and goat antimouse Cy3-conjugated secondary antibodies (1:500; Thermo Fisher Scientific). Following rewashing with PBS, slides were counterstained with either DAPI or Hoechst 33342 dye (Invitrogen) for 10 minutes and then mounted using Shandon ImmuMount mounting medium (Thermo Fisher Scientific). Samples were visualized the next day for FRET data acquisition on a Zeiss LSM 780 confocal microscope with pinhole set at 1 airy unit using 405-, 488-, and 568-nm excitation and a 363/1.4 oil objective lens (Carl Zeiss, Inc.). To assay FRET efficiency or dequenching of donor after photobleaching, a series of eight images of the Alexa-488 channel was taken. Cy3 within the nucleus was bleached after image 4 by scanning with the 561-nm laser line at maximum intensity. Alexa-488 intensity inside the nucleus were compared between the immediately prebleached image (image 4) and the postbleached image (image 5). Dequenching was defined as nuclear Alexa-488 intensity in image 4 divided by nuclear Alexa-488 intensity in image 5 similarly to the calculation of GFP/mCherry FRET. The remainder of the image sequence served as a control for focus stability. At least 10 cells per treatment were photobleached for each experiment. Experiments were performed at least 3 times.
To calculate FRET percentage, the fluorescence intensities of three ROIs, a region in close proximity to the cell (background), a region in the nucleus that was photobleached (bleached region), and a region of the nucleus that was not bleached (unbleached region), were selected, and data were acquired for both Cy3 and Alexa-488. The fluorescent intensities of Alexa-488 immediately before the bleaching and immediately after the bleaching were next background corrected by subtracting fluorescence intensity of the background region in the Alexa-488 channel of the same image. The prebleach and postbleach Alexa-488 corrected intensities were then used to calculate the percentage dequenching, which is a measure of FRET in this experimental design. A total of 10 images were analyzed per experimental condition. Percentage dequenching was calculated as follows: dequenching % = (Alexa488_corrected postbleach/Alexa-488_corrected prebleach) 3 100. In this measure, 100% represents a baseline with no change in fluorescence, indicative of no substantial FRET, although values greater than 100% are consistent with FRET prior to dequenching. At least 10 cells were selected at random for each experimental condition. Statistical analysis using analysis of variance and t test was carried out in GraphPad Prism (Graphpad Prism; RRID: SCR_002798).
Binding of receptor DNA to Hoechst dye
HPK1A and HPK1Aras cells were seeded on 22-mm glass slides (MatTek Corp.) at a concentration of 1 3 10 5 cells/well for 24 hours in DMEM containing 10% FBS. The next day, the cells were transfected with hVDR-GFP, hRXRaWT-GFP, hRXRamut-GFP, or DRIP205-GFP using FuGENE HD at a DNA/FuGENE ratio of 2 mg/6 mL as described previously under "Transfection," and cells were treated with experimental reagents for 4 hours prior to fixation as described in the text. The cells were next washed with PBS and fixed in 4% paraformaldehyde for 15 minutes. Cells were rewashed with PBS and stained with Hoechst 33342 dye (1 mg/mL) for 10 minutes at room temperature. Finally, cells were rewashed with PBS, and slides were mounted with Shandon Immu-Mount medium (Thermo Fisher Scientific). Imaging was carried out the next day using both the 488-and 405-nm lasers to compare colocalization of the GFP and Hoechst dye in the cells. Image analysis was carried out by selecting the nuclei in the images using the regions of interest tool in the Zeiss LSM 780 Image Examiner (Carl Zeiss, Inc.). Pearson's coefficient was measured in the ROI using the Zeiss Image Examiner to quantitate pixel-by-pixel colocalization of Hoechst dye (a DNA marker) with GFP within the nucleus (Carl Zeiss, Inc.).
Molecular modeling of RXRa
RXR structures were retrieved by searching for Protein Data Bank (PDB) entries containing any entity with .95% sequence identity to RXR. Forty-eight RXR-containing crystal structures were obtained. Only eight structures with resolved P244-N253 regions were retained for further analysis. The RXR structures were imported into the Molecular Operating Environment (MOE), a commercially available software package for molecular modeling and structural biology analysis (67, 68) . The MOE Protein Superpose application was used to overlay the eight RXR PDB structures based on their peptide backbones. The similarity between the RXR structures was quantified using the root-mean-square distance (RMSD), which is computed by taking the square root of the average of the squared distances between overlaid atoms. The RMSD values are reported in angstroms (1Å = 10 -10 m). The RMSD was computed on a per-residue basis using the Ca carbon atoms from corresponding residues in the overlaid RXR structures. Regions of RXR where the structural changes are small have low per-residue RMSD values (,2Å) whereas RXR regions where structural changes are large have larger per-residue RMSD values (.2Å). The average RMSD for the residues in the RXR structural core was 0.51Å, which indicates a large degree of structural similarity between core structures in the eight structures. The superposed RXR structures were grouped according to the position of Ser260, which produced three groups of structures representing three conformational states of RXR. The PDB codes and state designations are in Table 1 .
Statistical analysis
We used analysis of variance and t test in GraphPad Prism software. Results are presented as means 6 SE of at least eight independent measurements. Data were analyzed statistically by one-way analysis of variance followed by a post hoc test and Student's t test. Values represent mean 6 SE of at least 10 different cells. A P value of ,0.05 was considered significant. One asterisk or a single white circle indicates a significant difference with P , 0.05, double asterisks or two white circles indicate P , 0.01, and triple asterisks or three white circles indicate a P , 0.0001.
Results

Effects of 1a,25(OH) 2 D 3 treatment on nuclear localization of DRIP205
Effects of 1a,25(OH) 2 D 3 treatment on nuclear localization of endogenous DRIP205 in nontransformed HPK1A and ras-transformed HPK1Aras Cells
We have previously reported that 1a,25(OH) 2 D 3 treatment increases the nuclear localization of both endogenous VDR and RXR in nontransformed HPK1A cells (66) . To similarly control for possible effects of the fluorescent protein tag, we first assessed the nuclear localization of endogenous DRIP205 in the nontransformed HPK1A and the ras-transformed HPK1Aras keratinocytes by using antibodies directed against endogenous DRIP205. We incubated cells with conjugated Alexa-488 secondary Crystal structure of CAR/RXR heterodimer bound with SRC1 peptide, fatty acid, and 5b-pregnane-3,20-dione. 1XVP Holo1 Crystal structure of CAR/RXR heterodimer bound with SRC1 peptide, fatty acid, and CITCO. 1FM6 Holo2 The 2.1-Å resolution crystal structure of the heterodimer of the human RXRa and PPARg LBDs respectively bound with 9-cis retinoic acid and rosiglitazone and coactivator peptides. 1FM9 Holo2 The 2.1-Å resolution crystal structure of the heterodimer of the human RXRa and PPARg LBDs respectively bound with 9-cis retinoic acid and GI262570 and coactivator peptides. 1K74 Holo2 The 2.3-Å resolution crystal structure of the heterodimer of the human PPARg and RXRa LBDs respectively bound with GW409544 and 9-cis retinoic acid and coactivator peptides. 1XLS Holo2 Crystal structure of the mouse CAR/RXR LBD heterodimer bound to TCPOBOP and 9cRA and a TIF2 peptide containing the third LXXLL motifs. 1LBD Apo LBD of the human nuclear receptor RXRa. 1G1U Apo The 2.5-Å resolution crystal structure of the RXRa LBD in tetramer in the absence of ligand.
PDB codes and state of eight RXRs containing crystal structures with resolved P244-N253 regions used during analysis. The RXR structures were imported into the MOE software, aligned based on sequence, and then superposed based on the sequence alignment.
Abbreviations: 9cRA, 9 cis-retinoic acid; CAR, constitutive androstane receptor; CITCO, 6-(4-chlorophenyl)imidazo We previously used the Pearson correlation coefficient to compare VDR/RXRa colocalization in the nuclear compartment of the nontransformed and ras-transformed cells (66) . We showed that nuclear colocalization of VDR/ RXRa was impaired in the ras-transformed cells when compared with the nontransformed cells. However, transfection of the HPK1Aras cells with RXRamut-GFP or treatment with the MEK inhibitor UO126 significantly increased the nuclear colocalization of VDR/RXRa (66) . To further understand VDR/RXRa and DRIP205 interaction, we also used the Pearson correlation coefficient to assess VDR/DRIP205 colocalization using VDR-GFP and DRIP205-mCherry in the nuclear compartment. In HPK1A cells, treatment with 1a,25(OH) 2 D 3 significantly increased VDR/DRIP205 nuclear colocalization (0.56 6 0.03) when compared with vehicle (0.21 6 0.03, P , 0.0001; Fig. 5A and 5B). In contrast, in HPK1Aras cells, treatment with 1a,25(OH) 2 D 3 alone did not increase VDR/DRIP205 nuclear colocalization (0.26 6 0.03) when compared with vehicle (0.21 6 0.03, P . 0.05; Fig. 5C ). However, a combination of UO126 with 1a,25(OH) 2 D 3 (0.52 6 0.01, P , 0.0001) or treatment with UO126 alone (0.33 6 0.01, P , 0.007; Fig. 5C ) significantly increased VDR/DRIP205 nuclear colocalization when compared with vehicle-treated cells (Fig. 5C ).
RXRa phosphorylation on serine 260 affects RXRa/DRIP205 colocalization within the nucleus in ras-transformed HPK1Aras cells
The transcriptional regulation of 1a,25(OH) 2 D 3 has been suggested to involve not only VDR, but also the binding of RXRa to DRIP205 (21, 34, 35, 39, 69) . As previously stated, we also compared the nuclear colocalization of RXRa/DRIP205 in the nontransformed HPK1A and ras-transformed HPK1Aras cells pixel by pixel following cotransfection of RXRawt-GFP/ DRIP205-mCherry. We tested the significance of the data obtained using the Pearson correlation coefficient. In HPK1A cells, treatment with 1a,25(OH) 2 D 3 significantly increased RXRawt/DRIP205 nuclear colocalization (0.55 6 0.03) when compared with vehicle (0.22 6 0.02, P , 0.0001; Fig. 5D and 5E ). In HPK1Aras cells cotransfected with RXRawt-GFP/DRIP205-mCherry, a combination of UO126 and 1a,25(OH) 2 D 3 (0.51 6 0.02) significantly increased nuclear colocalization when compared with vehicle (0.21 6 0.03, P , 0.0001; Fig. 5F ). Also, treatment with UO126 alone (0.31 6 0.04) significantly increased nuclear colocalization (0.31 6 0.04) when compared with vehicle (0.21 6 0.03, P , 0.0001; Fig. 5F ). In contrast, treatment with 1a,25 (OH) 2 D 3 alone (0.23 6 0.02) did not increase nuclear colocalization when compared with vehicle (0.21 6 0.03, P . 0.05; Fig. 5F ). Furthermore, in HPK1Aras cells cotransfected with RXRamut-GFP/DRIP205-mCherry, combination of UO126 and 1a,25(OH) 2 D 3 (0.51 6 0.02, P , 0.0001) or treatment with 1a,25(OH) 2 D 3 alone (0.51 6 0.03, P , 0.0001) significantly increased nuclear colocalization to levels observed with RXRawt-GFP/DRIP205-mCherry treated similarly (Fig. 5F ) when compared with control (0.22 6 0.06, P , 0.0001; 
Effects of 1a,25(OH) 2 D 3 treatment on DRIP205 interactions with VDR and RXR using FRET
Effects of RXRa phosphorylation on VDR and DRIP205 interaction in nontransformed HPK1A and ras-transformed HPK1Aras cells using FRET
We used FRET to investigate interaction between VDR and DRIP205 after ligand addition in both cell lines (Fig. 6A and 6B) . The rationale was that although the statistical data obtained using the Pearson correlation coefficient could suggest that VDR and DRIP205 colocalize, it could not by itself show interaction. First, we used either DRIP205-GFP/VDR-mCherry or DRIP205-GFP/RXRa-mCherry tagged protein FRET pairs and compared it with untagged EGFP/mCherry FRET probes (data not shown). As expected, our results showed VDR/ DRIP205 heterodimeric interaction indicating that our FRET pairs were competent to form heterodimers. No FRET signal was observed with the negative untagged EGFP/mCherry control probes in both cell lines (data not shown). Next, we tested for VDR and DRIP205 interaction in both cell lines assaying FRET between VDR-mCherry and DRIP205-GFP or VDR-GFP and DRIP205-mCherry. A percentage-dequenching FRET efficiency baseline of 100% was set for FRET interaction. This means that any FRET value below 100% was considered as no interaction. In HPK1A cells cotransfected with VDRmCherry/DRIP205-GFP, treatment with 1a,25(OH) 2 D 3 alone (107.0% 6 1.9%) significantly increased VDR/DRIP205 interaction when compared with vehicle (97.1% 6 0.7%, P , 0.0001; Fig. 6C ). In HPK1Aras cells cotransfected with VDR-mCherry/DRIP205-GFP, combination of UO126 and 1a,25(OH) 2 D 3 (110.3% 6 2.0%) or treatment with 1a,25(OH) 2 D 3 alone (104.1% 6 0.9%) significantly increased VDR/DRIP205 interaction when compared with vehicle (94.3% 6 1.3%, P , 0.005) or UO126 treatment alone (96.90% 6 0.91%, P , 0.005; Fig. 6E ).
Effects of RXRa phosphorylation on VDR/LXXLL motif interaction in HPK1A and HPK1Aras cells
It has been shown that binding and interaction of DRIP205 coactivator to either VDR or RXR occurs through short sequences known as receptor interacting domains, nuclear interaction domains, or LXXLL motifs (21, 34, 35, 69) . The motif on the coactivator binds to the AF2-domain on the receptor creating a charge clamp that stabilizes the complex. We therefore used FRET to assess VDR/DRIP205 LXXLL motif interaction in both cell lines cotransfected with VDR-mCherry/LXXLL-GFP. In HPK1A cells, treatment with 1a,25(OH) 2 D 3 significantly increased VDR/DRIP205 interaction (103.8% 6 2.4%) when compared with vehicle (94.4% 6 0.9%, P , 0.0003; Fig. 6D) 
Mutation of DRIP205 LXXLL motif to AXXAA abrogates interaction with VDR
To closely observe the importance of the DRIP205 receptor interacting domain, we mutated the LXXLL amino acid sequence to AXXAA. We then used FRET as previously stated to assess the interaction of VDR/DRIP205 with the mutated LXXLL motif in both cell lines. Cells were cotransfected with VDR-CFP/AXXAA-YFP. In HPK1A cells, treatment with 1a,25(OH) 2 D 3 did not increase VDR/AXXAA interaction (92.54% 6 0.63%) when compared with vehicle (94.5% 6 1.2%, P . 0.05; Fig. 6G ). Similarly, in HPK1Aras cells, combination of UO126 and 1a,25(OH) 2 D 3 (95.01% 6 0.7%, P . 0.05) or treatment with 1a,25(OH) 2 D 3 alone (90.60% 6 0.7%) did not increase VDR/AXXAA interaction when compared with vehicle (92.70% 6 0.7%, P . 0.05) or UO126 treatment alone (91.8% 6 1.50%, P . 0.05; Fig. 6H ). This result further shows the importance of the LXXLL motif in DRIP205 interaction with the nuclear receptors.
RXRa phosphorylation at serine 260 impaired RXRa and DRIP205 interaction in HPK1Aras
We next determined interaction between RXRa and DRIP205. In HPK1A cells cotransfected with RXRawtmCherry/DRIP205-GFP, treatment with 1a,25(OH)2D3 significantly increased RXRawt/DRIP205 interaction (102.3% 6 1.1%) when compared with vehicle (91.01% 6 0.7%, P , 0.0001; Fig. 7A ). In HPK1Aras cells cotransfected with RXRawt-mCherry/DRIP205-GFP, a combination of UO126 and 1a,25(OH) 2 D 3 significantly increased RXRa and DRIP205 interaction (105.1% 6 1.3%) when compared with vehicle (94.1% 6 0.8%, P , 0.0001) or UO126 (97.6% 6 1.3%, P , 0.0001) or 1a,25(OH) 2 D 3 (97.3% 6 0.8%, P , 0.0001; Fig. 7C ) treatment alone. In contrast, treatment with 1a,25(OH) 2 D 3 alone did not increase RXRawt/DRIP205 interaction when compared with vehicle (P . 0.05) or UO126 treatment alone (P . 0.05; Fig. 7C ). When the cells were cotransfected with RXRamut-mCherry/DRIP205-GFP, treatment with 1a,25(OH) 2 D 3 alone significantly increased interaction (103.7% 6 1.92%) when compared with vehicle alone (93.2% 6 1.32%, P , 0.001) or UO126 (97.05% 6 0.87%, P , 0.001; Fig. 7E) . A similar effect was observed when 1a,25(OH) 2 D 3 was used in combination with UO126 (106.3% 6 1.43%) treatment alone.
RXRa phosphorylation at serine 260 impaired RXRa/LXXLL motif interaction in HPK1Aras cells
We next determined RXRa/LXXLL interaction in both cell lines by cotransfection with RXRawt-mCherry/LXXLL-GFP. In HPK1A cells, treatment with 1a,25(OH) 2 D 3 alone significantly increased RXRawt/LXXLL interaction (103.1% 6 1.5%) when compared with vehicle (93.4% 6 1.1%, P , 0.01; Fig. 7B ). In contrast, in HPK1Aras cells, cotransfection of RXRawt-mCherry/LXXLL-GFP and treatment with 1a,25(OH) 2 D 3 did not increase FRET interaction (97.31% 6 0.86%) when compared with vehicle (93.41% 6 0.83%) or UO126 (97.62% 6 1.21%, P . 0.05; Fig. 7D ) alone. However, combination of UO126 and 1a,25(OH) 2 D 3 significantly increased RXRa/ LXXLL interaction (103.5% 6 1.33%) when compared with vehicle (93.4% 6 1.1%, P , 0.005) or UO126 (97.62% 6 1.21%, P , 0.005; Fig. 7D ) treatment alone. In HPK1Aras cells cotransfected with RXRamutmCherry/LXXLL-GFP, treatment with 1a,25(OH) 2 D 3 alone (105.1% 6 1.14%) significantly increased RXRa/ LXXLL interaction when compared with vehicle (94.90% 6 0.60%, P , 0.0001) or UO126 (96.05% 6 0.71%, P , 0.0001; Fig. 7F ) treatment. A similar effect was observed in combined 1a,25(OH) 2 D 3 and UO126 treatment (106.0% 6 0.47%, P , 0.0001). This result shows that RXRa phosphorylation inhibits RXRa/ DRIP205 or RXRa/LXXLL motif interaction in the ras-transformed cells.
FRET between endogenous DRIP205 and VDR and RXRa nuclear receptors confirm results with tagged constructs
Finally, we carried out the similar FRET experiments to assess interaction between endogenous VDR/DRIP205 and RXRa/DRIP205. Cells were treated with or without ligand for 4 hours followed by costaining with antibodies that detects endogenous VDR/DRIP205 or RXRa/ DRIP205, respectively. In HPK1A cells costained with anti-VDR (Cy3)/DRIP205 (Alexa 488), treatment with 1a,25(OH) 2 D 3 significantly increased VDR/DRIP205 interaction (103.5% 6 0.5%) when compared with vehicle (91.81% 6 0.7%, P , 0.0001; Fig. 8A ). Similarly, in HPK1A cells costained with anti-RXRa (Cy3)/DRIP205 (Alexa 488), treatment with 1a,25(OH) 2 D 3 significantly increased interaction (102.2% 6 0.6%) when compared with vehicle treatment alone (91.8% 6 0.7%, P , 0.0001; Fig. 8B ). In HPK1Aras cells costained with anti-VDR/DRIP205, treatment with 1a,25(OH) 2 D 3 (104.1% 6 0.6%) or combination with UO126 (105.1% 6 0.5%) significantly increased interaction between VDR/ DRIP205 when compared with vehicle (93.4% 6 0.5%, P , 0.0001) or UO126 (95.9% 6 0.9%, P , 0.0001; Fig. 8C ) treatment alone. In HPK1Aras cells costained with anti-RXRa/DRIP205, combination of UO126 and 1a,25(OH) 2 D 3 significantly increased VDR/DRIP205 https://academic.oup.com/endointeraction (102.4% 6 0.6%) when compared with 1a,25(OH) 2 D 3 (88.56% 6 0.5%, P , 0.0001), vehicle (90.7% 6 0.9%, P , 0.0001), or UO126 (95.4% 6 0.4%, P , 0.0001; Fig. 8D ) treatment alone. Treatment with 1a,25(OH) 2 D 3 (88.56% 6 0.5%) alone did not significantly increase interaction when compared with vehicle (90.7% 6 0.9%, P . 0.05) or UO126 (95.4% 6 0.4%, P . 0.05; Fig. 8D ) treatment alone.
Effects of RXRa phosphorylation on RXRa/DRIP205 complex binding to DNA in nontransformed HPK1A and ras-transformed HPK1Aras cells We previously showed in ras-transformed cells that were singly transfected with either VDR-GFP or RXRa-GFP that RXRa phosphorylation on serine 260 affected both VDR and RXRa binding to DNA and chromatin (66) . In the current study, we cotransfected cells with either RXRawt-GFP/DRIP205-mCherry or RXRamut-GFP/DRIP205-mCherry. Following treatment as previously stated, cells were fixed and stained with Hoechst 33342, a widely used DNA-specific dye, which emits blue fluorescence under ultraviolet illumination when bound to DNA. Hoechst has a preference to bind to A/T-rich DNA sequences and highlights a subset of the genome. We measured binding (colocalization) of DRIP205 to DNA (Hoechst dye) and then evaluated the statistical significance of the data obtained using the Pearson correlation coefficient.
In HPK1A cells cotransfected with RXRawt-mCherry/ DRIP205-GFP, we found a direct correlation between RXRa and DRIP205 both binding to DNA. Treatment of cells with 1a,25(OH) 2 D 3 significantly increased RXRawt/ DRIP205 complex binding to DNA (0.55 6 0.02) when compared with vehicle (0.23 6 0.03, P , 0.0001; Fig. 9A ). Determination of the effects of RXRa phosphorylation, RXRa/DRIP205 interaction, and conformation change using molecular modeling
We used molecular modeling to investigate the structural implications of Ser260 phosphorylation on RXRa peptide binding to DRIP205 coactivator. We examined 48 RXR x-ray crystal structures retrieved from the PDB (codes listed in Table 1 ). Only 8 of the 48 RXR structures (PDB codes 1XV9, 1XVP, 1FM6, 1FM9, 1K74, 1XLS, 1G1U, and 1LBD; Table 1 ) had fully resolved P244-K275 regions. Because Ser260 is in the P244-K275 region, only these eight structures were carried forward in the analysis. In Fig. 10A , the sequences of the overlaid RXR structure are colored by RMSD value (green for ,1Å, yellow/orange for 1 to 4Å, and red for .4Å). The green-colored residues in Fig. 10A highlight the residues that form the structural core of RXR (average RMSD = 0.51Å), whose conformation changes little between the peptide-bound and nonpeptide-bound forms of RXR. The orange-and redcolored residues in Fig. 10A highlight the structurally variable regions of RXR (regions P244-K275 and F437-E456); these regions exhibit significant conformational differences between the holo and apo forms of RXR. In  Fig. 10B , the per-residue RMSD is displayed above the sequence as bars whose color and height reflect the RMSD values. Residues P244-K275 are colored light green and residues F437-E456 are colored cyan. The Ser260 residue is highlighted in blue. The large RMSD values above the P244-K275 and F437-E456 residues reflect the different conformations these regions exhibit. In the peptide-bound structures (Holo1 and Holo2; Fig. 11, i and ii) , the position of the P244-K275 region forces F437-E456 (R3) to adopt a folded conformation that partially forms the peptide-binding pocket of RXR. In the non-peptide-bound (Apo) structures (Fig. 11, iii) , the P244-K275 region changes to a conformation that Figure 11 . Model of RXRa interaction with DRIP205 coactivator to form active and inactive structures. (A) Conformational states of Ser260 in RXR structures. Structurally conserved resides are shown in white, the bound peptide is shown in yellow, retinoic acid is shown in space-filling mode, and Ser260 is annotated and rendered in space-filling mode. The P244-K275 region (R1 and R2) is shown in green, and the F437-E456 region (R3) is shown in cyan. In the peptide-bound structures [(i) Holo1 and (ii) Holo2], the P244-K275 region forces F437-E456 (R3) to adopt a conformation with two small helices that fold back toward the RXR structure and help create the peptide-binding pocket. In the non-peptidebound structure [(iii) Apo], the P244-K275 region (R1 and R2) moves to allow the F437-E456 region (R3) to adopt an extended helix that points away from the peptide-binding region and partially destroys the peptide-binding pocket. (B) Intramolecular interaction of Ser260 in RXR. (i) In the Holo1 state, the Ser260-Asn257 hydrogen bond stabilizes the N253-D263 loop, which forces the P244-N253 region (R2) into an extended conformation. (ii) In the Holo2 state, the peptide-binding pocket still exists, but the Ser260-Asn257 hydrogen bond has been disrupted, which allows the P244-N253 (R2) region to start coiling up into a helix as seen in the Apo structure. (iii) In the Apo state, Ser260 is fully exposed and pointing away from the RXR core. A portion of the R2 region becomes helical, and the R3 region adopts an extended helical conformation that contributes to forming the peptide-binding pocket.
allows the F437-E456 region to adopt an extended helical conformation that does not participate in forming the peptide-binding pocket.
Discussion
This study expands on our previous work on the mechanism of action of 1a,25(OH) 2 D 3 in ras-transformed keratinocytes (66) . In previous studies, we demonstrated that RXRa phosphorylation on serine 260 resulted in relative resistance to the growth inhibitory action of 1a,25(OH) 2 D 3 in ras-transformed cells (55) (56) (57) 60) . We further hypothesized that phosphorylation at serine 260 interfered with VDR and RXR nuclear localization, VDR/RXR heterodimer interaction, binding of the heterodimer complex to DNA, and transcriptional activation of VDR. Also, we speculated that blocking RXRa phosphorylation by the use of a MAPK inhibitor UO126 or a nonphosphorylatable RXRa mutant can reverse the effect by sensitizing ras-transformed keratinocytes to 1a,25(OH) 2 D 3 signaling. By comparing subcellular localization, VDR/RXRa interaction, and DNA binding in both nontransformed and ras-transformed cells, we have confirmed part of the hypothesis. We showed that VDR/RXRa heterodimer interaction and binding to DNA are both impaired in the ras-transformed cells.
One should note, however, that MAPK activation can have other effects independent of vitamin D resistance affecting vitamin D action. Indeed, an interesting observation made earlier by Dwivedi et al. (70) is that, in COS-1 cells, the ras-raf-MAPK pathway stimulates CYP24A1, the major catabolic pathway of 1,25(OH) 2 D and analogs (71) (72) (73) . The authors report that MAPK activation leads to phosphorylation of RXRa at ser260 and phosphorylation of Ets-1 at threonine 38, which then act cooperatively to enhance CYP24A1 promoter activity. These effects were reversed by treating cells with MAPK inhibitors or dominant negative mutants of ERK. All in all, it would appear that MAPK triggers a series of events that promotes inactivation of 1,25(OH) 2 D. Therefore, MAPK activation would further enhance the effect of vitamin D resistance that we observed previously through RXRa phosphorylation on serine 260, resulting in severely impaired antitumor effect of 1,25(OH) 2 D, further highlighting the complex regulation of vitamin D action. However, it remains to be established whether these effects can be generalized or are cell specific.
In the current work, we investigated further the association of VDR and RXRa with the DRIP205 coactivator. We first determined the subcellular localization of endogenous DRIP205. We demonstrated that inhibition of MAPK activity increased the nuclear localization of DRIP205 in ras-transformed keratinocytes. Next, we determined the role of DRIP205 in interacting with VDR and RXRa and the VDR/RXRa complex binding to chromatin. We previously reported that HPK1A and HPK1Aras cells express DRIP205 and RIP140 (60) . We therefore decided to first investigate the nuclear colocalization of DRIP205 with either VDR or RXRa. This was important as it is well documented that coactivator interaction with the VDR/RXRa heterodimer complex precedes the transcriptional activation of VDR (35) . We confirmed that VDR colocalizes with DRIP205 in both nontransformed and ras-transformed cells treated with 1,25(OH) 2 D 3 , suggesting that the effect observed was independent of RXRa phosphorylation in the rastransformed cells. Also, we demonstrated that in both the non-transformed and ras-transformed cell lines, VDR interacted with DRIP205 coactivator and its signature LXXLL motif in a ligand-dependent manner. These data suggest that RXRa phosphorylation on serine 260 does not directly affect association of VDR with DRIP205 in the ras-transformed cell line. Our findings are consistent with previous reports showing that VDR interacts with DRIP205 through its LXXLL motif in cell-free models (35, 39, 47, 74) . Importantly, our work was conducted in intact cells, highlighting the significance of these findings.
Our results showed that RXRa phosphorylation on serine 260 reduced both RXRa and DRIP205 colocalization and its interaction. As expected in our study, transfection of the ras-transformed cells with a nonphosphorylatable RXRa mutant or pretreatment with UO126 restored RXRa/DRIP205 nuclear colocalization and interaction. We also examined the interaction of the previously reported DRIP205 motif LXXLL that was demonstrated to be essential for binding to nuclear receptors. Rachez et al. (35) , using a cell-free system, showed that DRIP205 is the single protein that mediates direct interaction with both VDR and RXRa. The interaction of the VDR with coactivators such as DRIP205 as well as SRC1 and GRIP is mediated through LXXLL motifs that associate directly within the AF-2 region of nuclear receptors (69) . DRIP205 contains two LXXLL motifs (75) (76) (77) , a signature motif that is shared by a variety of cofactors (including SRC family members, PGC-1 family members, p300/CBP, and RIP140) and used for their binding to nuclear receptors (78) . Studies with isolated WT and reconstituted DRIP complexes containing mutations in DRIP205 LXXLL motifs have shown that these motifs are essential both for strong ligand-dependent interactions with nuclear receptors and for optimal nuclear receptor-mediated transcription in vitro (79, 80) and in vivo (81, 82) . Rachez et al. (35) demonstrated that a mutation in the second LXXLL motif (also called NR2 motif) of DRIP205 abolished its ability to bind the VDR/RXRa heterodimer and form a complex in the presence of 1a,25(OH) 2 D 3 . Structural studies for many nuclear receptors including DRIP205 have shown that the AF2-containing LBDs bear a similar three-layered a-helical sandwich structure with a central ligand-binding site in which the ligand is buried. In the unliganded (apo) state, the H12 helix of the AF2 motif extends away from the LBD core; however, upon ligand binding (holo state), it is folded against the LBD, with two conserved hydrophilic residues (glutamine and lysine) forming a charged clamp that mediates interactions with the a-helix LXXLL motif of coactivators (77, 78) .
Our results therefore suggest that in addition to the requirement for DRIP205 binding to VDR/RXRa, there is also a contribution from both VDR and RXRa binding to the LXXLL motif of DRIP205 in the presence of the ligand, suggesting the LXXLL motif contacts each subunit of the VDR/RXRa heterodimer (35) . The data therefore reinforces the key role of DRIP205 recruitment of the DRIP complex to the functional VDR/RXRa heterodimer in response to 1a,25(OH) 2 D 3 .
Furthermore, we showed through cotransfection studies and fluorescence microscopy of VDR/DRIP205-and RXRa/DRIP205-tagged chimeras that binding of the complex to DNA was also impaired in the rastransformed cells. There was a direct correlation of the VDR/RXRa heterodimer complex binding to either DRIP205 or VDR/RXRa/DRIP205 complex binding to DNA. Our results demonstrated that even though VDR colocalized and interacted with DRIP205 through its LXXLL motif, it did not increase binding in the rastransformed cells. Binding of VDR/RXR complex to DNA was only increased following the blocking of RXRa phosphorylation at serine 260. The current work thus lends additional support to our previous results using single transfection of VDR-or RXRa-tagged chimeras also showing impaired binding of both VDR and RXRa to DNA in the ras-transformed cells when compared with the nontransformed cells (66) . Using a cell-free system and chromatin immunoprecipitation assay, we furthermore demonstrated the importance of RXR phosphorylation on DNA-responsive elements and DRIP205 coactivator recruitment to the VDR/ RXRa complex in HPK1Aras (60) . In the current study, we expanded this work in intact cells showing alteration in interaction of VDR/RXRa/DRIP205 complex in rastransformed cells.
However, we also found that binding could be restored and increased by using either the MEK inhibitor UO126 or transfection with a nonphosphorylatable RXRa mutant, which blocks MAPK phosphorylation (66) . RXRa is believed to participate directly as a necessary heterodimeric partner in VDR-mediated transactivation (25, (83) (84) (85) (86) . Thus, mutations in the activation domain of RXRa or RXRa phosphorylation at serine 260 as observed in the ras-transformed cells could also blunt the ability of VDR to activate transcription (87) . These findings indicate that both receptors likely participate in comodulator interaction essential to transactivation and DNA binding.
We used molecular modeling to investigate the possible structural implications of Ser260 phosphorylation on RXRa peptide binding. It should be noted that the modeling work presented here is a comparative study of existing structural data, the goal of which was to generate a hypothesis of how Ser260 phosphorylation could possibly affect the ability of RXR to bind LXXLL motifs. The Holo1, Holo2, and Apo structures of RXR are compared in Fig. 11A and 11B . The RXRa structures all exhibit a highly conserved core (shown in white) along with two structurally variable regions, residues P244-K275 (shown in green) and residues F437-E456 (shown in cyan). Comparing the Holo1, Holo2, and Apo RXRa structures in Fig. 11A suggests that the P244-K275 and F437-E456 regions engage in concerted motion that interconverts RXRa between the peptide binding holo form and a peptide-nonbinding apo form. The V265-K275 region (R1) forms a helix in the Holo1 (Fig. 11A, i) and Holo2 (Fig. 11A, ii) structures that forces the F437-E456 region (R3) to fold into two small helices that help create the peptide-binding pocket. In the Apo structure (Fig. 11A,  iii) , the V265-K275 helix (R1) moves to allow the F437-E456 region (R3) to form an extended helix that produces a more open pocket that is less receptive to interaction with proteins that contain the LXXLL motif. In the process, the P244-N253 region (R2) converts from an extended or disordered conformation in the Holo form to a partial helix in the Apo structure.
The presence of Ser260 in the middle of the P244-K275 region suggests a structural explanation for the profound effect of Ser260 phosphorylation on RXR peptide binding. Examination of the Holo1 state (Fig. 11B,  i) shows an intramolecular hydrogen bond between the Ser260 side-chain hydroxyl group and the backbone carbonyl of Asn257, which forces residues N253-D263 into a loop conformation (N253-D263 loop) that pulls the P244-N253 region (R2) into an extended conformation quite different from the partial helix it adopts in the apo state. The Holo2 (Fig. 11B , ii) state is intermediate between Holo1 and Apo states; the Holo2 state still binds peptides, but the Ser260 no longer forms a hydrogen bond with N257, which disrupts the N253-D263 loop observed in the Holo1 structures and allows the P244-N253 region (R2) to begin adopting a helical conformation similar to the Apo form. In the Apo state (Fig. 11B, iii) , Ser260 is fully exposed to solvent and exhibits no intermolecular side-chain interactions with the rest of the protein. The P244-N253 region R2 is no longer extended and forms a helical region.
The previously mentioned structural observations suggest that the effect of Ser260 phosphorylation in RXR peptide binding arises from the influence of Ser260 phosphorylation on the conformational preferences of the P244-K275 region, which in turns influences the formation of the peptide-binding pocket. The Apo RXR structures have a fully exposed Ser260 residue that could easily accommodate phosphorylation both sterically and electrostatically, so phosphorylation is not expected to disrupt the Apo RXR conformation. In contrast, phosphorylation of Ser260 in the Holo1 structure would most certainly disrupt the observed Ser260-Asn257 intermolecular hydrogen bond that appears to stabilize the Holo1 state via the N253-D263 loop that forces an extended P244-N253 conformation. The Holo2 structures show that although the peptide-binding pocket can remain intact in the absence of the Ser260-Asn257 hydrogen bond, disruption of the Ser260-Asn257 hydrogen bond may help the RXR structure move toward the Apo state by allowing the P244-N253 region (R2) to begin forming the helical conformation observed in the Apo state.
Dong et al. (88) , investigating the functional roles of LXXLL motifs on glucocorticoid receptor (GR) signaling, hypothesized that mutation in the LXLL motifs would produce a conformational change resulting in loss of ligand (dexamethasone)-binding capacity to the ligandbinding pocket of the receptor. They used the solved crystal structure of human GR from PDB to determine the structural impact of LXXLL mutations on GR signaling. They determined that locations of the resolved residues were too far apart to directly affect the conformational change of the dexamethasone-binding pocket. Furthermore, as the residues were not close to the dimer interface or charge clamp that are critical for coactivator recruitment, mutations will likely affect ligand binding through destabilization of the hydrophobic interactions. Such disruption would overall affect the conformation indirectly affecting the ligandbinding pocket.
Our findings provide insights into the mechanisms involved in the partial response to the growth inhibitory action of 1,25(OH) 2 D 3 in ras-transformed keratinocytes. We provide additional evidence that RXRa phosphorylation at serine 260 not only reduces VDR/RXRa heterodimer interaction, but also blocks the interaction of the VDR/RXRa heterodimer to DRIP205 coactivator resulting in reduced, very weak to minimally detectable binding of the VDR/RXRa/DRIP205 complex to DNA. These findings provide the basis for future studies on designing optimal vitamin D therapy in cancer. We think that blocking MAPK phosphorylation of the RXRa would increase the sensitivity of cells bearing ras oncogene to vitamin D.
In summary, the comparison of existing RXR structures shows that Ser260 is located on a flexible loop whose conformation varies between the holo and apo forms of RXR. This suggests that Ser260 phosphorylation could affect RXR binding of LXXLL by biasing the RXR conformation away from the peptide-binding holo form and toward the non-peptide-binding apo form. This leads to the hypothesis that LXXLL binding by the S260A mutant of RXR is unaffected by phosphorylating conditions because S260A RXR cannot phosphorylate at position 260, and thus unlike WT RXR, the S260A RXR mutant will not be more biased toward the apo conformation in phosphorylating conditions. Future work to confirm this hypothesis would include obtaining an experimental structure of the S260A RXR bound to an LXXLL peptide to confirm that the S260A mutant of RXR can indeed bind the LXXLL peptide in the same manner as WT RXR.
